La pharmacocinétique (PK) des anticorps monoclonaux (mAbs) est sujette à d’importantes variations interindividuelles. Le récepteur néonatal au Fc des IgG (FcRn) et le statut immun à l’encontre de ces mAbs sont des déterminants de cette PK. La bioconjugaison des mAbs à des cytotoxiques entraîne une altération de leur PK. Nous montrons que le taux de couplage modifie l’affinité de ces espèces pour le FcRn à pH6. La proportion d’agrégats au sein des solutions d’anticorps armés augmente avec le taux de couplage et pourrait entraîner une altération de leur PK. Par ailleurs, cette agrégation est impliquée dans l’immunogénicité des mAbs, et nous avons donc cherché à identifier des acides aminés impliqués dans l’agrégation de mAbs indiqués en clinique. Il apparait que la nature biochimique de résidus des paratopes pourrait augmenter cette agrégation. Les anti-TNF- présentent très peu d'agrégats et figurent pourtant parmi les plus immunogènes chez l’Homme. Nous avons donc exploré le rôle des complexes immuns dans leur immunogénicité chez la souris. Il apparait que la présence du FcRn n’est pas à l’origine de l’immunisation contre ces mAbs, contrairement à celle des complexes immuns. Ces résultats donnent des pistes pour la production de mAbs plus efficients et mieux tolérés. / The pharmacokinetic (PK) profile of monoclonal antibodies (mAbs) shows interindividudal variability. The neonatal Fc receptor (FcRn) and the immounogenicity of these mAbs are determinative factors of mAb PK. Generation of antibody-drug-conjugates alters their PK profile. We show that the the affinity for FcRn at pH6 increases with the drug-to-mAb ratio, as does the amount of aggregates inside the mAb-drug-conjugate. The amount of aggregates could be responsible for an avidity effect towards FcRn. These aggregates are known to cause immunogenicity, so we studied biochemical determinants inside the aminoacid sequence of marketed mAbs. We show that the biochemical nature of some aminoacids inside the paratope has an impact on the amount of aggregation. Anti-TNF- mAbs show very little aggregation but are very immunogenic in humans. We studied the role of the formation of immune complexes in the immunization against anti-TNF- mAbs in mice, and showed that immune complexes, but not FcRn are essential in the immunization process against anti- TNF- mAbs. These results give leads towards the generation of more efficient, better tolerated mAbs.

A Aspergilose Broncopulmonar alérgica (ABPA) é uma doença complexa,desencadeada por uma reação de hipersensibilidade ao Aspergillus fumigatus, que apresenta vários estágios, sendo que no estágio mais grave, os pacientes apresentam bronquiectasias. O diagnóstico da doença é difícil e o maior problema é a falta de antígenos padronizados necessários para a determinação de anticorpos específicos. O objetivo do presente estudo é avaliar se os testes cutâneos com os análogos de Asp f 1 podem auxiliar no diagnóstico e no estadiamento da ABPA. Três grupos de pacientes classificados por testes sorológicos foram obtidos a saber 20 ABPA (16BQ+; 4BQ-), 25 possíveis -ABPA (14BQ+;11BQ-) e 24 asmáticos sem ABPA (11BQ+;13BQ-). Fizeram parte do estudo 10 pessoas sem asma . Todos foram submetidos a testes intradérmicos com três antígenos a-sarcina, mitogilina e estrictocina.Houve uma intensa reação a todos os antígenos e as reações produzidas foram semelhantes para os três antígenos. As reações de leitura tardia positivas à mitogilina foram biopsiadas. As biopsias de 2 (12,5%) dos pacientes BQ+ do grupo ABPA e 5 do grupo ABPA possível com BQ+ (35,6%) mostraram vasculite por depósito de imunocomplexos. 11 pacientes do terceiro grupo não apresentaram vasculite. O quarto grupo não apresentou reação tardia. Todos os pacientes com reação positiva apresentaram BQ+. alfa-sarcina, a mitogilina e a restrictocina diferenciaram pacientes com ABPA por testes intradérmicos e podem ser aplicados no diagnóstico da doença. A maior incidência de bronquiectasias foi encontrada no primeiro grupo (80%) e no segundo (56%). No terceiro grupo nenhum caso foi encontrado em 23 pacientes com asma e teste ID positivo ao aspergillus fumigatus todos os pacientes com vasculite tinham bronquiectasia. Há possibilidade de que as lesões produzidas nos pulmões sejam produzidas por vasculite. / Allergic Bronchopulmonary Aspergillosis (ABPA) is a complex disease, triggered by a hypersensitivity reaction to Aspergillus fumigatus. The disease diagnosis is difficult, and a major problem is the lack of standardized allergens for the determination of specific antibodies. The aim of the present study is to evaluate if intradermal (ID) tests with analogs of Asp f 1 can aid in the diagnosis and stage assessment of abpa. Three groups of patients classified by serological tests were obtained. 20 ABPA (16BQ+; 4BQ-), 25 possible-ABPA (14BQ+; 11BQ-), 24 asthmatic-ABPAfree (11BQ+; 13BQ-) and 10 asthma-free people were submitted to id tests with three antigens: mitogillin, a-sarcin and restrictocin. There was intense reaction to all three antigens and the response was similar. The positive reactions to mitogillin were biopsied. The skin biopsies of two (12,5%) bq+ patients of the first group and 5 BQ+ (35,6%) patients of the second one showed vasculitis by immune complexes (IC) deposition. 11 patients of the third group had negative biopsies. The fourth group didn\'t have late-reaction. All patients with positive reaction were BQ+. By ID test, alfa-sarcin, mitogillin and restrictocin could differentiate patients with abpa and can be applicable in disease diagnosis. The higher incidence of bronchiectasis was found in the first (80%) and second (56%) groups. In the third group, IC wasn\'t found in 23 asthma patients and id test was positive to A. fumigatus. All patients with vasculitis by IC had bronchiectasis. Therefore, the results indicate that this kind of pulmonary lesion is caused by vasculitis.

La Néphropathie à IgA est la glomérulonéphrite primitive la plus fréquente, responsable d’une évolution vers l’insuffisance rénale terminale dans 10 à 30% des cas après 20 ans d’évolution. Les déterminants de cette maladie sont nombreux, impliquant de multiples acteurs de l’inflammation, qu’ils soient cellulaires ou humoraux. La physiopathologie générale de la maladie est actuellement considérée comme se déroulant en quatre « coups », (i) la production d’IgA1 polymériques présentant un déficit de galactosylation de la région charnière, (ii) l’existence d’un élément circulant capable de complexer ces IgA1 anormales, pouvant être une IgG anti-glycane ou la portion soluble du récepteur de type I aux IgA (sCD89), (iii) la constitution de complexes immuns circulants et (iv) le dépôt glomérulaire de ces complexes, générant des lésions inflammatoires puis cicatricielles responsables de l’évolution vers la maladie rénale chronique. La médiation inflammatoire est impliquée à différents niveaux comprenant entre autres le rôle de l’infiltration de macrophages dans le tissu rénal, l’orchestration de cette réponse inflammatoire glomérulaire par les sous-populations de lymphocytes T et l’importance de l’activation du complément sur le déterminisme des lésions glomérulaires inflammatoires médiées par les complexes immuns déposés. Au cours de ce travail de thèse, l’implication de ces différents acteurs a été explorée. Les macrophages expriment le récepteur de type I aux IgA (CD89, issu du gène FCAR), dont une mutation de la portion intracytoplasmique modifie in vitro la transduction du signal. La première étude a visé à évaluer sur une grande cohorte rétrospective l’impact de cette mutation sur le risque d’occurrence de la maladie ainsi que son impact pronostique. Le rôle des sous-populations T a été abordé au cours d’une seconde étude, suivant l’hypothèse que l’orientation pro inflammatoire au cours de la NIgA pourrait être liée à un déficit de régulation par une sous-population de lymphocytes T, les Tregs. Cette étude prospective a évalué la représentation de la sous-population CD4+CD25+CD127low et le profil d’expression génique de gènes prototypiques des sous-populations Th1, Tregs et Th17. Le rôle du complément comme médiateur inflammatoire à l’interface entre les complexes immuns à IgA1 et les cellules mésangiales a été exploré par une étude in vitro. La mutation 844 A->G de FCAR n’a pas été associée à un risque supplémentaire de développer la maladie et n’impactait pas le pronostic des patients. L’étude des lymphocytes T n’a pas montré de différence de quantité de cellulesCD4+CD25+CD127low entre patients et volontaires sains et ne suggérait qu’une tendance en faveur d’un déficit fonctionnel de régulation (plus faible expression des gènes FoxP3, IL10, TGFβ chez les patients). Enfin, des fragments issus de l’activation et de la protéolyse par le facteur I de C3 ont été mis en évidence par immunoblot et spectrométrie de masse au sein des complexes immuns générés artificiellement en présence de serum. Ces études suggèrent qu’une modification du rôle fonctionnel du CD89 n’impacte pas le devenir de la NIgA, ce qui est en défaveur d’un rôle critique de ce récepteur dans la pathogénie de la maladie. La tendance au déficit fonctionnel Tregs nécessite d’être confirmée au sein d’un effectif plus conséquent et présentant une forme plus active de la maladie, mais elle corrobore deux autres études comparables dans leur méthodologie. Enfin, le rôle du complément se situe à l’interface entre les complexes immuns et les effecteurs inflammatoires glomérulaires tels que les cellules mésangiales / IgA Nephropathy (IgAN) is the most common primary glomerulonephritis, leading to end stage renal failure in 10 to 30% of cases after 20 years. This disease is determined by numerous inflammatory players, including cells and molecules. The pathogeny of the disease is likely to be driven by a 4 « hits » model, (i) increased systemic production of aberrantly O galactosylated polymeric IgA1, (ii) the existence of circulating abnormal IgA1 binding element, which could be either an anti-glycan IgG or the soluble fragment of the main IgA receptor (sCD89), (iii) the formation of circulating immune complexes, and (iv) the glomerular deposition of these complexes, that accounts for a variable local inflammation leading to scarring processes and finally to the chronic kidney disease. Inflammatory mechanisms operate at several levels, including the macrophage cells infiltration in the kidney tissue, the orchestration of the immune response by T-cells subsets, including regulatory T-cells, and the role of complement activation to induce the glomerular inflammatory response from the immune complexes deposition. In the present work, we aimed to explore the implication of these inflammation response players. Macrophages express the type I IgA receptor (CD89, downstream from its gene FCAR), whose function can be affected in vitro by a common mutation of its intracytoplasmic portion. A first study evaluated the impact of this mutation on the risk to develop the disease as well as on the global prognosis. A second study evaluated the role of T-cell subsets during IgAN, following the hypothesis that the pro-inflammatory balance of the disease could be a consequence of a defect in the immune regulation by the Tregs. This prospective study aimed to assessing the frequency of CD4+CD25+CD127low cells in peripheral blood and the characteristic gene expression profile from Th1, Th17 and Tregs subsets. The role of complement as an inflammatory player at the interface between IgA1 containing immune complexes and mesangial cells was explored by an in vitro study. The single nucleotide polymorphism 844 A->G of FCAR had no impact neither on disease risk of occurrence neither on the renal survival. The T-cell subsets study failed to demonstrate any difference in the proportion of CD4+CD25+CD127low cells and only suggested a defect in functional activity of Tregs, according to a lower expression of FoxP3, IL10, TGFβ genes. The third in vitro study demonstrated by immunoblot and mass spectrometry the presence of C3 breakdown products accompanying IgA1 based engineered immune complexes formed in presence of normal immunoglobulin depleted serum. The lack of effect of the mutation of FCAR on the IgAN prognosis is not in favour to a critical role of this receptor on the pathogeny of the disease. The trend in the functional defect of Tregs subset needs to be confirmed in a larger study, including patients with a more severe form of their disease. This result is however consistent with two other studies displaying a similar methodology. The role of complement is confirmed to be a key player, as it is likely to act at the interface between the IgAN particular immune complexes and mesangial cells

While clearly different in their aims and means, classification and diagnosis both try to accurately label the disease patients are suffering from. For systemic lupus erythematosus (SLE), this is complicated by the multi-organ nature of the disease and by our incomplete understanding of its pathophysiology. Hallmarks of SLE are the presence of antinuclear antibodies (ANA), and multiple immune-mediated organ symptoms that are largely independent. In an attempt to overcome limitations of the current sets of SLE classification criteria, a new fourphase approach is being developed, which is jointly supported by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). This review attempts to delineate the performance of the current sets of criteria, the reasons for the decision for classification, and not diagnostic, criteria, and to provide a background of the current approach taken.

Octapharma tillverkar Octagam, en lösning innehållande humant immunglobulin för intravenös administrering, vars huvudkomponent är immunglobulin G (IgG). Aggregerade IgG förknippas med aktivering av komplementsystemet i frånvaro av antigen. Denna ospecifika aktivering av komplement har tidigare rapporterats orsaka biverkningar hos patienter. För att undvika detta använder Octapharmas laboratorium för kvalitetskontroll en metod som kallas test av antikomplementär aktivitet, för kontroll av batcher av Octagam innan de släpps ut på marknaden. Denna metod har flera problem, t.ex. låg tillgänglighet av viktiga reagens. Syftet med detta projekt var därför att undersöka om en alternativ metod, CIC-C1q ELISA, kunde mäta aktiveringen av komplementsystemet på immunglobuliner genom att testa olika batcher av IgG och värmebehandlade IgG-prover för att bedöma om det fanns en korrelation mellan resultaten från de två metoderna. Resultaten visade att det inte fanns någon korrelation mellan ACA-testet och CIC-C1q ELISA. Varken normala IgG-batcher eller värmebehandlade prover uppvisade någon tydlig korrelation. Den enda fördelen som C1q kan ha är att den gav ett högt resultat för en batch som tidigare har rapporterats orsaka biverkningar hos patienter, medan svaret i ACA-testet var relativt normalt. CIC-C1q ELISA metoden har dock visat sig ha sina egna problem eftersom standardprover ger inkonsekventa värden och mer tester behöver utföras för att hitta spädnings-linjäritet. / Octapharma manufactures Octagam, a liquid preparation of highly purified human immunoglobulin for intravenous administration, the main component of which is immunoglobulin G (IgG). Aggregated IgG is associated with activation of the complement system in the absence of antigen. This non-specific activation of complement has been reported to cause adverse reactions in patients. To avoid this, Octapharma's quality control laboratory uses a method called the determination of anti-complementary activity (ACA) in Immunoglobulin, for control of all batches of Octagam before release. This method has several problems, such as low availability of critical reagents. Therefore, the aim of this project was to investigate whether an alternative method, CIC-C1q ELISA, could measure the activation of the complement system on immunoglobulins by testing different batches of IgG and heat-treated IgG samples to assess whether there is a correlation between the results of the two methods. The results showed that there was no correlation between the ACA test and the CIC-C1q ELISA. Neither normal IgG batches nor heat-treated samples showed a clear correlation. The only advantage the C1q may have is that it gives a high response for a batch that has been reported to cause adverse reactions in patients, while the response in the ACA test was relatively normal. If this can be demonstrated by testing similar batches, it may be beneficial to continue testing the C1q ELISA. However, this method has also been shown to have its own problems, such as the standard sample giving inconsistent values, and more work is needed to find the linearity of the dilution.

Das Verständnis der Immunpathogenese des systemischen Lupus erythematodes (SLE) hilft, das komplexe Krankheitsgeschehen zu verstehen und neue Therapiestrategien zu entwickeln. Die Krankheitsmanifestationen des SLE sind im Wesentlichen Folge von Autoantikörpern, Immunkomplexen und Zytokinen. Insbesondere die Neigung zu unterschiedlichen Autoantikörpern macht das Wesen der Erkrankung aus; die genauen Spezifitäten der Autoantikörper führen zu ganz unterschiedlichen Organmanifestationen. Diese Übersichtsarbeit stellt den klinisch relevanten Stand des Wissens zur SLE-Pathogenese dar – mit dem Ziel, ein für den klinischen Einsatz nützlichesModell zu etablieren, das auch hilft, die neuen Therapieansätze einzuordnen.

In this study, we demonstrated that membrane immunofluorescence (MIF) with canine erythrocytes is a much more sensitive diagnostic technique compared with the Coombs test to detect auto-antibodies on RBC. We also demonstrate how the evaluation of the MIF test can be made more precisely which results in a more clear interpretation. Till nowadays the Evans syndrome (combined thrombocytopenia and anemia) is not very well diagnosed in dogs. Only a few studies with low animal numbers tested auto-antibodies on RBC and thrombocytes. Here we describe the frequency of Evans syndrome based on the evaluation of a large data set with 557 dogs. The novelty of the thesis also lies in making a research of the amount of CICs in sera of AIHA/AITP patients is described as well as the cytotoxic potential of patient’s sera for canine leucocytes. These new aspects of diagnosis (AIHA) and pathogenesis (AIHA/AITP) are not only relevant for dogs but also for humans and can be used for better differential diagnosis in medicine. The new findings with respect to circulating immune complexes and cytotoxicity are also offer new therapeutic concepts. Besides, the study has resulted in the characterization of monoclonal antibodies which allow for the detection of so far undetectable canine differentiation antigens (CD molecules) on canine erythrocytes (CD235) and thrombocytes (CD42a). The identified mAbs are useful in the identification of relevant target structures for autoantibodies on these cells.

Follicular dendritic cells (FDCs) reside in primary B-cell follicles and in the light zones of germinal centers (GCs) in secondary follicles, where their dendrites interdigitate forming extensive networks intimately interacting with B-cells. In GCs, FDCs can be found at the edges attached to the supporting reticular fibers. They trap and arrange immune complexes (ICs) in vivo and in vitro in a periodic manner with 200–500Å spacing and provide both antigen-specific and non-specific accessory signals to B-cells. FDCs exist in resting and activated states, with two characteristically different phenotypes. In their activated state, FDCs upregulate the expression of accessory molecules and cytokines important in the FDC-B cell interaction in GCs. We sought to determine the mechanisms influencing the transition of FDCs from a resting to an activated state in GCs and their impact on T-cell dependent (TD) and independent (TI)-GC reactions (GCRs). We found that IC-FDC interactions via FDC-FcgammaRIIB induce the upregulation of FDC-FcgammaRIIB, -ICAM-1, and -VCAM-1, at both the protein and mRNA levels. We also reported for the first time the expression of TLR-4 on FDCs. Moreover, engagement of FDC-TLR4 with LPS activated NF-kappaB, up-regulated expression of important FDC-accessory molecules, including FcgammaRIIB, ICAM-1, and VCAM-1, and enhanced FDC accessory activity in promoting recall IgG responses. Moreover, IC-activated FDCs produced IL-6 and FDC-IL-6 promoted GCRs, somatic hypermutation (SHM) and IgG production. Further, we reported that binding of FDCs to collagen coated surfaces induced restoration of their dendritic processes and networks in vitro. In addition, we designed an FDC-supported in vitro model capable of induction and assessment of primary human antibody responses to protein antigens characterized by class-switching and affinity maturation. Uniquely, we generated TI immune responses to TD protein Ags in the complete absence of T cell help in vivo and in vitro. In the presence of FDC-associated second signals such as BAFF and C4BP, FDC- FcgammaRIIB-periodically trapped-ICs induced the production of Ag-specific IgM, GC-development and plasmablast-differentiation in anti-Thy-1-pretreated nude mice. Purified murine and human B cells cultured in vitro with IC-bearing FDCs also showed the production of antigen–specific IgM within just 48 h.